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Introduction
Airway management is an essential skill that all anesthesi-
ologists require. As the current airway management methods 
are still not optimal, anesthesiologists need to be continuously 
updated with new developments related to airway devices and 
techniques [1]. Among these developments, high-flow nasal 
oxygenation (HFNO) is particularly prominent. Although the 
use of this technique is spreading globally, there are some con-
troversies regarding its indications and the advantages of having 
the required skills to use it. Therefore, in this narrative review, 
we focus on the new emerging airway management skill of per-
forming HFNO, and we describe the potential role of HFNO 
based on the current state of knowledge.
High-flow Nasal Oxygenation (HFNO)
HFNO is a method that provides oxygen at a high flow rate 
of over 15 L/min (which is the maximum flow rate for a conven-
tional nasal cannula) through a patient’s nasal opening [2]. The 
device is able to titrate the fractional inspired oxygen (FiO2) to 
up to 1.0 and to consistently deliver a highly oxygenated flow to 
the alveoli because of its ability to provide higher flow rates than 
that of the usual inspiratory flow and to reduce the entrainment 
of room air [2]. HFNO generates a low level of continuous pos-
itive airway pressure of 2.7–7.4 cmH2O, facilitates the washout 
of the nasopharyngeal dead space, reduces the nasopharyngeal 
resistance, increases alveolar recruitment, decreases the work 
of breathing, and prevents the development of atelectasis and 
bronchospasm [2–4]. Specially designed equipment is required 
for HFNO because the oxygen flow should be at adequately high 
temperatures and humidity levels, which prevents the feeling of 
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dryness in the nasal cavity of patients and promotes tolerance 
for the high-flow rate [3]. Additionally, humidified and heated 
inspired oxygen lessens the energy cost involved in gas condi-
tioning [5], prevents mucociliary damage, and facilitates muco-
ciliary clearance [3,6]. 
Traditional use of HFNO
HFNO has proven highly effective for patients admitted to 
the intensive care unit (ICU) [7] or to the post-anesthetic care 
unit after surgery [3]. It is evident that HFNO enhances oxy-
genation in patients who develop hypoxemic acute respiratory 
failure and that it helps to avert the need for reintubation after 
extubation in the ICU [3]. A meta-analysis reported that HFNO, 
when employed postoperatively, reduced the length of hospital 
stay for adult patients [8]. Following this meta-analysis report, 
another study confirmed that postoperative HFNO reduced the 
length of hospital stay and the incidence of re-admission to the 
ICU in the case of cardiac surgical patients with pre-existing re-
spiratory diseases [7]. 
The reported side effects from the trials were minor, such 
as being sensitive to noise, feeling hot, and developing a runny 
nose [3]. The nasal interface of the HFNO system is composed 
of soft silicone with a wider bore compared to that of traditional 
nasal prongs. HFNO is generally well tolerated compared to oth-
er means of oxygen supplementation, such as a low-flow nasal 
cannula or a facemask [9]; further, patients can tolerate HFNO 
with a flow rate of up to 100 L/min without experiencing any 
discomfort, and some may even fall asleep [4].
HFNO has potential contraindications, including in cases in-
volving severe nasal obstruction, copious nasal bleeding, recent 
nasal trauma, recent nasal surgery, significantly raised intracra-
nial pressure, and base-of-skull fractures [10].
Use for anesthesia management
Recently, HFNO has been applied during anesthesia man-
agement, including during the anesthesia induction period and 
intraoperative period (Fig. 1). For this purpose, a system with 
different characteristics (OptiflowTM; Fisher & Paykel Health-
care, New Zealand) has been developed. Optiflow consists of a 
flow meter, humidifier, heating system, heated non-condensing 
circuit, nasal cannula, head strap, and an oxygen connector for 
gas supply (Fig. 2). It is different from the Airvo system (Air-
voTM system, Fisher & Paykel Healthcare Ltd., New Zealand) in 
its use in the ICU as the FiO2 is fixed at 1.0 in order to facilitate 
the installation of the device within 2–3 min [11]. The oxygen 
flow rate can be increased to up to 70 L/min, which is more 
than that of Airvo (2–60 L/min). Due to the FiO2 of 1.0 and its 
higher flow rate, Optiflow is mostly indicated for adults and 
children who weigh more than 10 kg. Airvo is more appropriate 
than Optiflow for children who weigh less than 10 kg due to the 
proper titration of FiO2 to less than 1.0 (range: 21–100%) and 
the flow rate of less than 20 L/min. The heating and active hu-
midifying of oxygen flow performed in Optiflow are similar to 
those in Airvo (37℃ and 44 mgH2O/L). It is recommended that 
this equipment be turned on approximately 5 min before its use 
to ensure adequate humidification and heating [10]. 
Conventional Oxygenation Methods
When general anesthesia is induced and a neuromuscular 
blocking agent is administered, the risk of hypoxemia arises after 
the induction of anesthesia if the facemask ventilation is inad-
equate and if tracheal intubation is difficult or has failed. In the 
case of difficult oxygenation during the induction of anesthesia, 
a high risk of severe complications, such as hemodynamic in-
stability, dysrhythmias, hypoxic brain injury, cardiac arrest, and 
even death, develops [12]. One effective method to minimize 
hypoxemia-related complications during the induction of anes-
thesia is adequate oxygenation. 
The oxygenation process during the induction of anesthesia 
can be divided into 2 phases based on the time points at which 
they are performed: preoxygenation and peroxygenation. Pre-
Fig. 1. Recent areas of use for high-flow 
nasal oxygenation, including during 
the anesthetic induction period and 
intraoperative period.
Loss of consciousness Intubation
Preoxygenation
Apneic oxygenation
Awake intubation
Airway surgery
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oxygenation is defined as the administration of oxygen before 
the induction of anesthesia, and its purpose is to maximize the 
amount of a ‘safe’ apnea time (apnea time without hypoxemia) 
after the induction of anesthesia and to delay the onset of hy-
poxemia if airway management is unexpectedly difficult [12,13]. 
Peroxygenation is the oxygenation performed from the time 
point at which anesthesia is induced until when the airway is 
completely secured. After the induction of anesthesia, a patient’s 
spontaneous breathing can either be maintained or stopped. In 
the latter case, the usual method is the application of intermit-
tent positive pressure ventilation via a facemask. If this is not 
possible, an alternative method is the insufflation of oxygen into 
the pharyngeal cavity, and this method is called ‘apneic oxygen-
ation.’
Preoxygenation via a facemask
For adults, the conventional method of preoxygenation is to 
provide oxygen using an FiO2 of 1.0 with a flow rate of 10–12 
L/min through a tightly fitting facemask placed over a patient’s 
nose and mouth [14,15]. The duration of preoxygenation should 
be titrated to denitrogenate the expiratory reserve and residual 
lung volume [16]. It is recommended to then confirm ade-
quate preoxygenation via an end-tidal oxygen partial pressure 
(EtO2) that exceeds 90%. In healthy adults, this endpoint can 
be achieved within 3–5 min when using tidal volume breathing 
through a facemask [17].
During preoxygenation, the method via which the patient 
breathes is crucial, and this affects the time needed for adequate 
oxygenation [16]. The 2 most representative methods are tidal 
volume breathing for 3 min and vital capacity breathing for 8 
breaths within 60 s [18]. Adequate preoxygenation enables a 
healthy adult to endure apnea for approximately 7–10 min with-
out developing hypoxemia [18].
Apneic oxygenation 
Apneic oxygenation can be employed to further delay the 
onset of desaturation. Employing apneic oxygenation can result 
in additional time to consider and attempt alternative airway 
management options when the airway cannot easily be secured. 
While the patient is in this less stressful condition, it is critical 
for the physician to focus on preventing an emergency situation 
and on making the right decision for the patient’s safety. 
A B C
Fig. 2. Equipment for high-flow nasal oxygenation (OptiflowTM, Fisher & Paykel Healthcare, New Zealand). (A) OptiflowTM consists of a flow meter, 
humidifier, heating system, heated non-condensing circuit, nasal cannula, head strap, and an oxygen connector for gas supply. (B) Nasal cannula. (C) 
Humidifier and heating system (© Fisher & Paykel Healthcare 2018. Used with permission).
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The concept of apneic oxygenation was established in 1908.1) 
The underlying physiology involves the passive movement of 
oxygen from the nasopharynx or the oropharynx to the alveoli; 
consequently, oxygen is taken up into the bloodstream even 
without active lung expansion [19,20]. This gas movement oc-
curs because oxygen and carbon dioxide differ in the flow rates 
associated with their absorption and excretion between the 
alveoli and bloodstream (O2: 250 ml/min and CO2: 8–20 ml/
min). This creates a sub-atmospheric pressure in the alveoli and 
a pressure gradient between the upper airway and the alveoli. 
Owing to this, oxygen is drawn from the pharynx into the alve-
oli. Therefore, if oxygenation were insufflated through the nasal 
or oral (buccal) route, it would prevent rapid desaturation even 
when a patient is apneic [21]. There are several available devices, 
such as nasal prongs, nasopharyngeal catheters, oropharyngeal 
catheters, an adapted Ring-Adair-Elwin (RAE) tube, and a mod-
ified laryngoscope, that currently exist for this purpose.
Oxygenation insufflation via a nasal cannula or prongs
Apneic oxygenation through a nasal catheter or via prongs, 
with an oxygen flow rate of 3–10 L/min, is generally useful in 
delaying desaturation in adult patients with physical statuses of 
American Society of Anesthesiologists (ASA) 1 or 2 [22]. In a 
retrospective study involving 728 patients [23], the incidence 
of desaturation (peripheral capillary oxygen saturation [SpO2] 
< 93%) was decreased from 23% to 17% by the implementation 
of apneic oxygenation (with an oxygen flow rate of 15 L/min) 
via a nasal cannula. Likewise, in a study involving 127 patients 
with intracranial hemorrhage who required rapid-sequence in-
duction of anesthesia in the emergency department [24], nasal 
prongs with an oxygen flow of 5–15 L/min during apnea re-
duced the incidence of desaturation (SpO2 < 90%) from 29% to 
7%. In obese patients (with a mean body mass index [BMI]: 31.2 
kg/m2), nasal prongs with an oxygen flow of 5 L/min extended 
the safe apnea time (SpO2 ≥ 95%) from 3.5 to 5.3 min [25]. An 
oxygen flow of 10 L/min via nasal prongs together with an ox-
ygen flow of 15 L/min via a facemask for 3 min increased the 
EtO2 even in the case of a gas leakage around the facemask [26]. 
Oxygenation insufflation via a pharyngeal tube
A previous study [27] involving 56 adult patients classified 
as ASA 1–2 demonstrated that the administration of 5 L/min 
of oxygen via a nasopharyngeal catheter was a superior method 
in preventing desaturation compared to providing oxygenation 
via nasal prongs; the possible reason for this is that a nasopha-
ryngeal catheter delivers oxygen more effectively to the alveoli 
because of the shorter distance from the oxygen outlet to the 
laryngeal inlet. The insufflation of oxygen at a flow rate of 10 L/
min via a RAE tube with its tip placed into the oral cavity (buccal 
route) extended the median safe apnea time (tracheal oxygen 
concentrations > 94%) from 447 to 750 s in adult patients [28]. 
However, in 1 out of 10 patients, the SpO2 decreased to less than 
95% at the 9.5 min time point, and in another patient, the SpO2 
fell to less than 50% due to the soft tissues occluding the tip of 
the RAE tube [28]. A similar study was performed on obese 
patients with BMIs of 30–40 kg/m2 in which apneic oxygenation 
with a flow rate of 10 L/min via a RAE tube having an internal 
diameter of 3.5 mm extended the median safe apnea time (SpO2 
≥ 95%) from 296–750 s [29]. In infants and small children with-
out cardiopulmonary diseases, oxygen insufflation at a rate of 
4 L/min through a tube attached to the side channel of a video-
laryngoscope extended the safe apnea time (SpO2 ≥ 95%) by an 
average of 30 s (mean time: from 131 to 166 s) [30].
Limitations of conventional apneic oxygenation
Apneic oxygenation devices that provide oxygen at a flow 
rate of less than 15 L/min have several limitations. First, the re-
sulting FiO2 is unpredictable and limited due to the entrainment 
of room air [21]. Second, the airflow is cold and dry, impairing 
the mucociliary function and thereby leading to a risk of trig-
gering bronchoconstriction. Third, the tip of a nasopharyngeal 
catheter or of a RAE tube can be misplaced or occluded by the 
surrounding tissues, thereby resulting in unexpected desatura-
tion. Fourth, oxygen insufflation via a tube that is attached to the 
side channel of a laryngoscope can be performed only when the 
laryngoscope is placed in the patient’s oropharynx. Lastly, when 
oxygen insufflation is performed while the patient is apneic, the 
clearance of carbon dioxide from the body cannot be expected 
[31].
HFNO during the Induction of Anesthesia
The efficacy of HFNO therapy in extending the safe apnea 
time before the airway is secured has been examined via several 
clinical studies, the focus of which could be categorized into the 
following topics: preoxygenation, induction of general anesthe-
sia, rapid-sequence induction, and awake tracheal intubation 
(Table 1). 
Preoxygenation
Non-obese adults
One of the benefits of HFNO is that it can easily and com-
fortably be applied to a patient who is awake until anesthesia is 
induced. A study compared HFNO with an oxygen flow of 60 L/
min for 3 min with oxygenation via a facemask (with an oxygen 
1)Volhard F. Uber kunstliche Atmung durch Ventilation der Trachea und 
eine einfache Vorrichtung zur hytmischen kunstlichen Atmung. München 
Medizinische Wochenschrift 1908; 55: 209-11.
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flow of 10 L/min) in 10 adult volunteers who were awake [32]. 
The resulting mean EtO2 was similar between both techniques 
(86 kPa for HFNO and 89 kPa for a facemask). Nevertheless, 
in the case of HFNO, the EtO2 decreased to 49 kPa when the 
volunteers opened their mouths, indicating that HFNO may be 
effective only with the mouth closed. 
In another observational study, HFNO with an oxygen flow 
of 70 L/min was applied to 21 adult volunteers who were awake, 
and it was observed that while the volunteers were closing their 
mouths, the EtO2 increased from 14–17% to 78–92% in 3 min 
[33]. Nevertheless, in half of the volunteers, the EtO2 did not 
reach 90%. In addition, 1 patient experienced discomfort, and 
the test was stopped midway; further, an additional 4 patients 
reported experiencing moderate discomfort (5 or 6 on a visu-
al analogue scale). Although it may be technically difficult to 
measure the EtO2 accurately during HFNO, it is also possible 
that HFNO may not reliably increase the EtO2 during preoxy-
genation for 3 min. In addition, patients in respiratory distress 
situations inevitably need to breathe with an open mouth, and 
it may be difficult for them to follow instructions requiring 
them to close their mouths [34]. The optimal parameters for the 
application of HFNO, such as the duration of preoxygenation, 
breathing pattern, or mouth status, need to be determined. In 
reported studies, different durations, ranging between 3–5 min, 
of HFNO were applied before the start of anesthesia induction 
[10,32,35–37]. To determine the optimal preoxygenation time 
with HFNO, apart from the EtO2, new criteria, such as the oxy-
gen reserve index sensor, should be considered in future clinical 
trials.
Obese adults
In obese patients, when preoxygenation is carried out 
through a facemask, the safe apnea time period is as short as 
1–3 min following preoxygenation compared with 7–10 min 
in healthy adult patients [18,38]. This is due to obesity-related 
physiological changes such as decreased functional residual 
capacity, increased oxygen consumption, and increased closing 
volume [15]. In a study involving 33 morbidly obese patients 
(BMI ≥ 35 kg/m2) [39], HFNO at a flow rate of 50 L/min with 
the patient’s mouth closed was superior to facemask oxygenation 
in achieving a high arterial partial pressure of oxygen (PaO2). 
After 3 min of preoxygenation with the patient in a 30° head-up 
position, the median PaO2 was 380 mmHg in the HFNO group 
and 337 mmHg in the facemask group. None of the patients 
developed complications due to epistaxis or gastric aspiration 
when using HFNO. Therefore, in obese patients, the efficacy of 
HFNO is increased by placing the patient in a head-up position.
Pregnant women
In obstetric patients, it is particularly important to make sure 
that the EtO2 reaches over 90% by employing at least 3 min of 
tidal volume breathing of 100% oxygen [19,40] because the rate 
at which difficult intubation occurs in these patients may be 10 
times higher than in the general population [12,41]. In addi-
tion, the safe apnea time period is relatively short due to several 
pregnancy-related changes such as airway edema, decreased 
functional residual capacity, increased oxygen consumption, and 
a higher risk of aspiration, as well as due to emergency surgery 
[40].
A computational model that simulates the effects of apneic 
oxygenation during rapid-sequence induction of anesthesia 
in obstetric women has indicated that the increase in FiO2 to 
up to 1.0 extends the safe apnea time [42]. The successful use 
of HFNO in a pregnant woman with severe cardiopulmonary 
disease has been reported in the case of a 27-year-old pregnant 
woman with acute respiratory distress syndrome and heart 
failure who required an emergency Cesarean section [11]. The 
patient had dyspnea and exhibited significant mouth breathing, 
and her SpO2 was 80%. Oxygen at a flow rate of 9 L/min via a 
facemask increased the SpO2 to 95%, and HFNO at a flow rate of 
70 L/min with an FiO2 of 1.0 further increased the SpO2 to 98% 
within 5 min even though the patient breathed predominantly 
through her mouth. After the induction of anesthesia, tracheal 
intubation was successfully performed with the SpO2 main-
tained at 98%.
In contrast, the results of another study have cast a doubt on 
the efficacy of HFNO [35] in pregnant women: following HFNO 
for 3 min (30 L/min for 30 s, followed by 50 L/min for 150 s), an 
EtO2 of 90% was achieved in merely 44 out of 73 (60%) pregnant 
women. In addition, although HFNO received similar scores as-
sociated with the comfort of its use to those of a facemask, only 
56% of women preferred HFNO to the facemask. These results 
are similar to those associated with non-pregnant patients.
HFNO for apneic oxygenation
After the induction of anesthesia and a neuromuscular block-
ade, oxygenation is usually performed by intermittent positive 
pressure ventilation via a facemask. When a facemask is used, 
the mask needs to be removed while attempting tracheal intuba-
tions, and thus, no oxygen is supplied during these attempts. If 
the time taken for tracheal intubation is prolonged and if diffi-
culties, such as in advancing the tracheal tube over a fiber-optic 
bronchoscope (which has successfully been inserted into the 
trachea), are encountered while performing the mask ventila-
tion, the risk of hypoxemia arises. Apneic oxygenation may be 
performed by the insufflation of oxygen through a RAE tube, a 
nasopharyngeal airway, or a short tracheal tube.
With HFNO, the nasal cannula does not need to be removed 
during attempts at laryngoscopy or fiber-optic bronchoscopy, or 
535Online access in http://ekja.org
KOREAN J ANESTHESIOL Kim and Asai 
during the insertion of a supraglottic airway and this increases 
the stability of the oxygenation. Moreover, there is a low prob-
ability of the occurrence of problems that are associated with 
the incorrect positioning of the device, which are more likely to 
occur with a buccal RAE tube. This prevents the need for clini-
cians to abandon ongoing intubation attempts too early due to 
the occurrence of desaturation, and it allows for sufficient time 
for them to focus on performing the tracheal intubation and 
on any maneuvers required [43]. In addition, the nasal cannula 
used for HFNO does not interfere with the application of a face-
mask when additional mask ventilation is needed. 
In adults
In 48 neurosurgical adult patients [10], the efficacy in in-
creasing the PaO2 between HFNO with an oxygen flow of 50 L/
min and an oxygen flow of 10 L/min through a facemask was 
compared. After 5 min of preoxygenation, the median PaO2 was 
significantly higher in the case of HFNO (471 mmHg) than in 
that of facemask oxygenation (357 mmHg). However, after the 
induction of anesthesia, the PaO2 decreased significantly in the 
HFNO group but not in the facemask group in which bag-mask 
ventilation was performed. This suggests that HFNO is more 
efficient than facemask oxygenation in ensuring a high PaO2 be-
fore the induction of anesthesia, but HFNO is less effective than 
facemask ventilation in maintaining a high PaO2. Nevertheless, 
7 patients in the facemask group required the use of airway ad-
juncts such as oropharyngeal airways, but none of the patients in 
the HFNO group required them, suggesting that HFNO is more 
easily incorporated. 
A male patient who had acute epiglottitis requiring emergen-
cy tracheal intubation [44] exhibited the following characteris-
tics: an airway assessed as a Mallampati score of 2, a thyromental 
distance of > 6 cm, poor dentition, adequate mouth opening and 
neck range of movement, and an easily palpable cricothyroid 
membrane. Despite the administration of intravenous antibiot-
ics and steroids, the airway obstruction progressed rapidly and 
required airway intervention. HFNO at a flow rate of 70 L/min 
was used in combination with the target-controlled infusion 
(TCI) of propofol, thereby allowing spontaneous breathing. The 
minimum oxygen saturation was 96% following tracheal intuba-
tion.
Oxygenation can be more difficult to perform in obese pa-
tients because the incidences of difficult mask ventilation and 
tracheal intubation may increase with obesity. The head-up po-
sition is helpful to maximize the efficacy of apneic oxygenation 
by reducing atelectasis and the subsequent pulmonary shunting 
[12,29]. Another study conducted on obese patients demonstrat-
ed that HFNO at a flow rate of 50 L/min resulted in the highest 
PaO2 value after 3–5 min of preoxygenation in morbidly obese 
patients and that the PaO2 decreased as the preoxygenation du-
ration was extended up to 7 min [39]. Therefore, the appropriate 
duration of preoxygenation using HFNO remains to be deter-
mined.
In children
Compared to adults, children are more prone to the risk of 
rapid desaturation in the order of seconds after the cessation of 
ventilation due to their decreased functional residual capacity, 
higher oxygen consumption, increased closing capacity, and 
higher risk of airway collapse [17,45]. A study has demonstrated 
that the mean desaturation time until the SpO2 reached 90% was 
significantly shorter in children (160 s) than in adolescents (382 
s), and it was substantially shorter in infants (97 s). In fact, the 
incidence of desaturation is common in children (4–10% during 
induction of anesthesia and 20% during tracheal intubation) 
[18]. Therefore, in children, optimal oxygenation strategies are 
crucial in order to extend the duration of safe apnea.
HFNO may extend the safe apnea time in children. In a study 
involving 48 children who were under 10 years with normal 
airways [46], in the facemask group, bag-valve ventilation was 
ceased and the jaw thrust was maintained whereas in the HFNO 
group, the flow rates of 2 L/kg/min, 35, 40, and 50 L/min were 
applied based on the body weight, and the jaw thrust method 
was performed during apnea. The main hypothesis was that the 
safe apnea time (time taken for the SpO2 to reach 92%) in the 
case of HFNO would be more than double the length of the ap-
nea time in the facemask group and the results confirm that this 
hypothesis was true. 
In another study involving 60 children, aged 1–6 years, 
weighing 10–20 kg, HFNO at a flow rate of 2 L/kg/min with 
an FiO2 of 1.0, HFNO at a flow rate of 2 L/kg/min with an FiO2 
of 0.3, and low-flow nasal oxygenation at a flow rate of 0.2 L/
kg/min with an FiO2 of 1.0 were compared [47]. Bag-valve 
mask ventilation was ceased when the target EtO2 of > 90% was 
reached. Apnea was terminated when the SpO2 was less than 
95%, transcutaneous carbon dioxide (tcCO2) reached 65 mmHg, 
or apnea duration reached 10 min. The SpO2 had decreased to < 
95% within 10 min in all the HFNO (FiO2 0.3) patients and in 3 
of the low-flow nasal oxygenation patients (17%), but it did not 
decrease in any of the HFNO (FiO2 1.0) patients, indicating that 
HFNO at a flow rate of 2 L/kg/min with an FiO2 of 0.3 is not 
effective. The tcCO2 exceeded above 65 mmHg within 10 min 
in 16 (80%) HFNO patients with an FiO2 of 1.0 and in 13 (72%) 
low-flow nasal oxygenation patients. In the case of HFNO with 
a flow rate of 2 L/kg/min and an FiO2 of 1.0, the median safe ap-
nea time was 7.6 min with a range of 5.2–10 min. Therefore, in 
children, HFNO with a flow rate of 2 L/kg/min and an FiO2 of 
1.0 can maintain the SpO2 for 10 min; however, there is a higher 
risk of hypercapnea with this technique, and therefore, it may be 
useful for surgeries that last between 5–6 min. It is not known 
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whether or not a higher flow rate (e.g., 4 L/kg/min) with an FiO2 
of less than 1.0 can be effective.
HFNO for rapid-sequence induction of anesthesia
In the operating rooms
HFNO may also have a potential role during rapid-sequence 
induction of anesthesia in the operating room. In a study involv-
ing 80 adults who were receiving rapid-sequence induction of 
anesthesia, the efficacy of oxygenation was compared between 
HFNO at a flow rate of 70 L/min and facemask oxygenation at a 
rate of 10 L/min [36]. The lowest SpO2 up to 1 min after tracheal 
intubation was similar between the techniques, but the SpO2 
decreased to < 96% in 7 patients (18%) in the facemask group 
whereas this was not observed in the HFNO group. None of the 
patients developed complications, such as the regurgitation of 
gastric contents, and there was no significant difference in the 
duration of the safe apnea time between HFNO (median: 116 s) 
and facemask (median: 109 s).
In another study involving 40 adult patients receiving rap-
id-sequence induction of anesthesia for emergency surgery, the 
efficacy between HFNO at the rate of 70 L/min and facemask 
oxygenation at the rate of 12 L/min were compared [48]. In the 
HFNO group, HFNO was maintained throughout the induction 
period whereas in the facemask group, the jaw was kept thrust 
out without bag-mask ventilation. In all the patients, the trachea 
was intubated successfully and there were no significant differ-
ences in the PaO2 between the groups. Nevertheless, it took sig-
nificantly longer to intubate the trachea in the HFNO group (the 
mean of 248 s) than in the facemask group (123 s). The authors 
of the report state that this difference was not due to any appar-
ent difference in procedural difficulty; however, the difference 
was quite marked. One of the reasons might be that the presence 
of a nasal cannula mechanically or psychologically facilitated a 
more careful time-consuming laryngoscopy and tracheal intu-
bation.
These results indicate that HFNO with the jaw thrust is an ef-
ficient method to prevent desaturation within 3–4 min of apnea 
during rapid-sequence induction of anesthesia in adults even if 
cricoid pressure is being applied.
Outside the operating rooms
Securing the airway is frequently more difficult outside the 
operating rooms than inside [49,50]. This is because outside the 
operating room, the unstable physiological status of patients, 
such as being affected by a cardiopulmonary disease, having a 
low cardiac output, or being in hypermetabolic states, limits the 
efficiency of preoxygenation and peroxygenation. In addition, 
emergency procedures, poor planning, less skilled staff, and 
the inadequate availability of equipment increase the incidence 
of difficult intubation to up to approximately 12% [43,51,52]. 
Therefore, tracheal intubation is associated with a high inci-
dence of hypoxemia, which is the most commonly associated 
complication (approximately 19–26%) [51,53] that is linked to 
hemodynamic deterioration, cardiac arrest, and death [12,54]. 
The incidence of death related to airway management has been 
reported to be 38-fold higher in the emergency department and 
58-fold higher in the ICU than in the operating rooms [12]. 
Meta-analyses have shown that oxygenation through a nasal 
cannula at various flow rates is effective in preventing desatu-
ration in patients who received emergency tracheal intubation 
[20,43]. In a study involving 101 adult patients who required 
rapid-sequence induction of anesthesia and intubation in the 
ICU [52], the efficacy of HFNO was compared with that of a 
non-rebreathing bag reservoir facemask combined with a na-
sopharyngeal catheter. For the HFNO group, HFNO at a flow 
rate of 60 L/min with an FiO2 of 1.0 was used for 3 min before 
the induction of anesthesia (preoxygenation) and was continued 
after the induction of anesthesia and during tracheal intubation. 
For the facemask group, 15 L/min of oxygen was provided for at 
least 3 min before the induction of anesthesia, and after the in-
duction, the facemask was removed, a nasal cannula was placed, 
and 6 L/min of oxygen was insufflated. The median of the lowest 
SpO2 was significantly higher in the HFNO group (100%, range: 
95–100%) than in facemask group (94%; 83–99%). Episodes of 
severe hypoxemia (SpO2 < 80%) were significantly lower in the 
HFNO group (2%) than in facemask group (14%); further, 1 car-
diac arrest due to hypoxemia occurred in the facemask group. A 
multivariate analysis indicated that HFNO was an independent 
factor that prevented severe hypoxemia. 
Nevertheless, HNFO may not be effective in improving ox-
ygenation when tracheal intubation is required in hypoxemic 
patients. In a study involving 119 patients who had acute hypox-
emic respiratory failure that required rapid-sequence induction 
and intubation (respiratory rate > 30 breaths/min, FiO2 require-
ment > 50%, PaO2/FiO2 < 300 mmHg) [55], either HFNO at a 
flow rate of 60 L/min with an FiO2 of 1.0 or facemask oxygen-
ation at a flow rate of 15 L/min was used. There was no signif-
icant difference in the lowest SpO2 level (92% in HFNO group 
and 90% in facemask group) and in the occurrence of severe 
hypoxemia involving an SpO2 < 80% during tracheal intubation 
(16 [26%] in the HFNO group and 13 [22%] in the facemask 
group). 
Similarly, another study that compared the efficacy of HFNO 
at a flow rate of 50 L/min and that of bag-valve-mask ventilation 
at a flow rate of 10 L/min in 40 critically ill patients who suffered 
hypoxemic respiratory failure (PaO2/FiO2 < 300 mmHg) [34], 
the lowest mean SpO2 during tracheal intubation and the occur-
rence of severe hypoxemia (SpO2 < 80%) were similar between 
the groups.
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In a report on 49 adult patients who required rapid-sequence 
induction due to severe acute hypoxemic respiratory failure in 
the ICU (respiratory rate > 30 breaths/min, FiO2 requirement ≥ 
50%, PaO2/FiO2 < 300 mmHg) [56], the efficacy of preoxygen-
ation with HFNO at a flow rate of 60 L/min with an FiO2 of 1.0 
together with non-invasive ventilation was compared with that 
of non-invasive ventilation performed on its own. HFNO plus 
non-invasive ventilation resulted in improved oxygenation and 
less frequent episodes of desaturation (SpO2 < 80%). Therefore, 
HFNO combined with non-invasive ventilation can reduce the 
incidence of severe hypoxemia during rapid-sequence induction 
of anesthesia in patients with severe acute hypoxemic respirato-
ry failure.
In a prospective observational study that investigated the 
efficacy of HFNO at a flow rate of 60 L/min during emergen-
cy tracheal intubation in 71 adult patients in the ICU, in the 
operating room, or in the emergency department, the median 
(range) apnea time was 80 (30–480) s [37]. Significant desatura-
tion (reduction in SpO2 to > 10% after induction of anesthesia) 
occurred in 5 patients (7%) who underwent acute respiratory 
failure (2 patients) or who had difficulty maintaining airway 
patency during apnea (3 patients). There were no complications 
resulting from the use of HFNO. 
In the ICU, patients’ conditions in relation to their respiratory 
diseases and the techniques used in the control and intervention 
groups are varied. The intubation protocol including intuba-
tion equipment, patient positioning, preoxygenation approach, 
operators, and medications administered have not been stan-
dardized [57]. This may be a reason for the discrepancies among 
out-of-hospital studies. Moreover, the definitions of clinical 
outcomes vary between studies. For example, the standard that 
is taken into consideration to define hypoxemia is usually the 
SpO2 value, which is the starting point of the steep slope on the 
oxygen dissociation curve of hemoglobin [58]. Nevertheless, de-
saturation can be defined differently, which may be another rea-
son for the conflicting results. Therefore, the efficacy of apneic 
HFNO compared to that of low-flow nasal apneic oxygenation is 
still unclear in emergency airway management in the ICU [3,20]. 
At least it is now apparent that HFNO alone may not be benefi-
cial to patients who suffer severe respiratory failure [34,55]. This 
may be because pulmonary shunting or easily collapsed airways 
diminish the benefits of HFNO. To overcome this limitation, 
other techniques that provide high positive airway pressure may 
be required [58].
Complications
Hypercapnea
One major potential problem in relation to apneic oxygen-
ation via HFNO is excessive hypercapnea. A study has demon-
strated that the partial pressure of carbon dioxide (PaCO2) 
increased with the speed of 3 mmHg/min during apneic oxy-
genation via HFNO at a flow rate of 50 L/min [10]. The PaCO2 
was significantly higher during apnea with HFNO than during 
bag-mask ventilation, but the resultant rise in the PaCO2 with 
HFNO seemed tolerable because the highest PaCO2 value was 
approximately 65 mmHg after the completion of tracheal intu-
bation. Flow rates of up to 70 L/min may be required to achieve 
the maximum clearance of carbon dioxide. In contrast, carbon 
dioxide accumulation was similar between HFNO and facemask 
preoxygenation during rapid-sequence induction during emer-
gency surgery [36,48] potentially due to a short observation 
period and the increase in carbon dioxide at a more rapid rate 
during the first minute following the onset of apnea. The clear-
ance of carbon dioxide during HFNO may be superior to that 
resulting from a low-flow oxygen delivery system [59]. 
In children aged up to 10 years [46], the mean tcCO2 that 
was measured at the end of apnea was 62 mmHg (range 49–79 
mmHg), and the mean rate of the increase in carbon dioxide was 
2.4 mmHg/min (range 0.2–3.9 mmHg/min). However, the rate 
of increase in carbon dioxide was not significantly lower when 
HFNO was combined with the jaw thrust method compared to 
when jaw thrust was used in isolation during apnea. In a study 
involving children aged up to 6 years [47], the tcCO2 increased 
at a median rate (range) of 4.1 (2.2–5.3) kPa/min in response to 
HFNO with an FiO2 of 1.0, and the rate of increase in the tcCO2 
was similar to that observed in the low-flow nasal oxygenation 
group. It has also been demonstrated that the younger the child, 
the faster the increase in the tcCO2 during apnea. These results 
imply that the efficiency in carbon dioxide clearance via HFNO 
is not prominent in children. This may be because the increase 
in carbon dioxide is higher in children than in adults and in 
younger children than in older children due to their higher met-
abolic demands. 
The application of HFNO interrupts the earlier detection of 
a rise in carbon dioxide and of airway obstruction compared to 
when bag-mask ventilation is used. Therefore, the transcutane-
ous monitoring of carbon dioxide [10,46] and the use of oxygen 
reserve index sensors may help in minimizing this risk and in 
optimizing the utilization of HFNO.
Gastric insufflation
Gastric insufflation is a theoretical complication resulting 
from HFNO because HFNO generates positive airway pressure. 
The increase in the nasal flow rate to 10 L/min is known to 
cause a 1.2 cmH2O increase in the nasopharyngeal airway pres-
sure, as observed when healthy volunteers breathed with their 
mouths closed when HFNO was being used [4], and thus, the 
airway pressure would increase to around 3 cmH2O at 30 L/min 
and to around 12 cmH2O at 100 L/min. 
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No serious complications, such as gastric insufflation, regur-
gitation, or pulmonary aspiration of gastric contents, have so far 
been reported even in the case of morbidly obese patients [36,39]. 
The number of studies on this subject is still limited, and thus, 
the true risk of gastric insufflation associated with the use of 
HFNO during anesthesia remains to be elucidated.
Settings of HFNO for the induction of anesthesia
Flow rate
Reports on the use of HFNO have indicated various high-flow 
rates such as 50 L/min [10,34,35,39], 60 L/min [32,37,52,55,56], 
or 70 L/min [33,36,48]. One study has demonstrated that the 
median intratracheal FiO2 significantly increased from 67% to 
93% as the flow rate increased from 15 L/min to 45 L/min [60]. 
Similarly, another study has demonstrated that increasing the 
flow rate of HFNO from 10 L/min to 50 L/min can yield a high-
er FiO2 [61]. Therefore, using a higher flow rate of greater than 
50 L/min is advisable to obtain the maximal effects of oxygen-
ation. 
Generally, HFNO is well tolerated by patients who are awake 
[35,36], but some of them may experience moderate or severe 
discomfort when a flow of 50–70 L/min is used [10,33]. There-
fore, it may be prudent to start HFNO with a relatively low flow 
rate (30–40 L/min) when a patient is awake and then to increase 
the flow rate (50–70 L/min). When a patient cannot tolerate a 
high flow, the flow should immediately be reduced to 30–40 
L/min, and once the patient has lost consciousness, the flow 
should be increased back to 50–70 L/min [10,35,36,48]. Con-
cerning children, the adequate flow rate has been indicated to 
be 2 L/kg/min for those weighing 0–15 (or 20) kg, 35 L/min for 
those weighing 15 (or 20) –30 kg, 40 L/min for those weighing 
30–50 kg, and 50 L/min for those weighing > 50 kg [46,47].
FiO2
As the FiO2 increases, the safe apnea time gets extended. 
In addition, a study has demonstrated that an increase in the 
FiO2 from 0.9 to 1.0 yielded a greater increase in the safe apnea 
time compared to an increase in the FiO2 from 0.21 to 0.9 [62]. 
Therefore, the FiO2 should usually be set to 1.0 in order to max-
imize the safe apnea time in adults including in morbidly obese 
patients [39] and in those requiring rapid-sequence induction of 
anesthesia [36,52]. 
In children, HFNO with an FiO2 of 0.3 may not be as efficient 
in extending the safe apnea time when compared to HFNO with 
an FiO2 of 1.0 [47]; therefore, when HFNO is used, the FiO2 
should be kept high. 
Breathing method
There is still little evidence with regard to which breathing 
method is the best. In some studies, patients were asked to 
maintain normal breathing [32,33] whereas in other studies, 
deep breathing was preferred [35]. One clear characteristic is 
that the efficacy of HFNO in oxygenation is reduced when the 
patient’s mouth is open [2]. In a study [63] in which HFNO 
with a flow rate of 35 L/min was applied in postoperative car-
diac surgery adult patients, the mean nasopharyngeal positive 
airway pressure was 2.7 cmH2O when the patient’s mouth was 
closed whereas it was only 1.2 cmH2O when the mouth was 
open. Similarly, in another study [64], the increase in the flow 
rates of HFNO resulted in increased mean airway pressures of 
0.7 cmH2O per every 10 L/min when the mouth was closed, and 
the increased rate of airway pressure significantly reduced to 0.4 
cmH2O when the mouth was open. Further [60], the median of 
mean airway pressure significantly increased from 0.4 cmH2O 
to 2 cmH2O as the oxygen flow was increased from 15 L/min 
to 45 L/min, but significantly decreased from 2 cmH2O to 0.6 
cmH2O when the mouth was open. However, the FiO2 was not 
significantly different between when the mouth was closed or 
open with HFNO at a flow rate of 45 L/min [60]. In a study in 
which the EtO2 was measured during HFNO at a flow rate of 60 
L/min [32], HFNO increased the EtO2 when the patient’s mouth 
was closed (86 kPa) whereas it failed to increase the EtO2 when 
the patient’s mouth was open (49 kPa). 
Another crucial point to consider during HFNO is that the 
patency of the upper airway is essential to provide adequate 
oxygenation [17]. The patency of the upper airway needs to be 
maintained using a head tilt [37], jaw thrust [36,37,46–48], chin 
lift [36,37], or the insertion of a pharyngeal airway [47]. 
Theoretically, deep breathing through the nose with the 
mouth shut would be the best patient status for preoxygenation 
[32,33,35,39].
 HFNO for Awake Intubation
Awake tracheal intubation is another technique for securing 
the airway for which HFNO may be valuable. Patients under-
going awake fiber-optic intubation are at risk of desaturation 
due to underlying airway diseases, obesity, or sudden complete 
airway obstruction that can be caused by oversedation or top-
icalization [65]. The use of HFNO has a theoretical advantage 
with regard to providing oxygenation during awake fiber-op-
tic intubation. This was confirmed by an observational study 
involving 50 adult patients [66] in which HFNO at a flow rate 
of 50–70 L/min was used during awake fiber-optic intubation. 
HFNO increased the median (range) of SpO2 from the baseline 
value of 98 (83–100)% to 100 (93–100)%, and none of the pa-
tients exhibited desaturation below the baseline SpO2 during the 
procedure. The median (range) of the EtCO2 was 4.8 (3.5–6.7) 
kPa after securing the airway. HFNO was also successfully used 
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during surgical tracheostomy performed on a sedated patient 
with upper airway obstruction secondary to an infective acute 
leukemic mass [67].
HFNO for Airway Surgery
Upper airway surgery often requires repetitive tracheal in-
tubations and extubations during the procedure to allow access 
to the surgical field and to allow the manipulation required. 
It is therefore necessary to use specialized methods to reduce 
stressful conditions by extending the safe apnea time and by 
preventing hypoxemia [68]. There are several oxygenation tech-
niques for airway surgery, such as transtracheal or transglottic 
jet ventilation, controlled mechanical ventilation using a small 
sized tracheal tube, and intermittent apneic ventilation [69]. 
Among these techniques, jet ventilation is the least preferred 
compared to the other techniques due to a resulting higher risk 
of barotrauma. The ideal method may be the tubeless technique 
that enables an optimal view of the surgical field and prevents 
tracheal tube-related injuries to the airways. The use of HFNO is 
a revolutionary oxygenation technique for airway surgery and it 
may replace the use of a tracheal tube during laryngomicrosur-
gery (Table 2). 
Reported use
Patel and Nouraei [59] were the first to report the use of 
HFNO during airway surgery. They used the technique in 25 
adult patients who were undergoing hypopharyngeal or laryn-
gotracheal surgeries, such as for benign laryngeal conditions, for 
obstructive sleep apnea, or for benign or malignant head and 
neck conditions. Their study included 12 obese patients and 9 
patients with stridor. The median BMI (range) was 30 (18–52) 
kg/m2. The median apnea time was 14 min, with the longest 
duration being 65 min. None of the patients exhibited desatura-
tion, i.e., an SpO2 of < 90%, when HFNO at a flow rate of 70 L/
min was used. Further, none of the patients experienced compli-
cations, such as cardiac arrhythmia, due to an increase in carbon 
dioxide during apnea.
Booth et al. [70] employed a ‘traditional’ use of HFNO 
during airway surgery by maintaining spontaneous breathing. 
In 30 adult patients who underwent laryngotracheal surgeries 
due to laryngotracheal stenosis or papilloma, HFNO at a rate 
of 70 L/min was applied while anesthesia was maintained with 
TCI propofol, thereby maintaining spontaneous breathing. 
The median duration of spontaneous breathing (range) was 44 
(18–100) min. Only 1 patient experienced desaturation due to 
a miscalculated remifentanil overdose, and tracheal intubation 
was required during the surgery. In another 3 patients, the SpO2 
decreased to less than 90% during laser surgery when the FiO2 
was reduced to 0.3. Nevertheless, the SpO2 increased rapidly 
when the FiO2 was increased back to 1.0.
In another report on 28 adult patients who were undergoing 
airway surgeries, apneic oxygenation was provided via a unique 
system called the Perioperative Insufflatory Nasal Therapy 
system at a flow rate of 80 L/min [71]. In 4 patients, the SpO2 
decreased to 85–90%, lasting for less than 2 min at several time 
points, following the injection of rocuronium. The oxygen satu-
ration was increased by the jaw thrust method and by increasing 
the flow rate to 120 L/min following the removal of the suspen-
sion laryngoscope or the insertion of a supraglottic airway. A 
different HFNO system (Optiflow) has a maximal flow rate of 
only 70 L/min; therefore, the rescue technique of increasing the 
flow rate to up to 120 L/min is not feasible with this system. 
HFNO has also been successfully used in patients with diffi-
cult airways. For example, in a 55-year-old male who had severe 
supraglottic-pharyngeal stenosis, HFNO with a flow rate of 70 
L/min and an FiO2 of 1.0 was applied, and the patient remained 
apneic for 26 min with the use of propofol, remifentanil, and 
rocuronium [72]. After the scar tissue was transected along the 
lateral epiglottic border resulting in the partial release of the 
stenotic lesion, the laser-safe tracheal tube was inserted through 
the opening. Until the time point at which the tracheal tube 
was inserted, the SpO2 was maintained at greater than 90%. In 
another report on a male patient who was morbidly obese with 
a BMI 40 kg/m2 and who had a neck circumference of 45 cm, 
mouth opening of 2 finger breaths, and Mallampati score of 4, 
HFNO at a flow rate of 60 L/min allowed for the performance of 
a 14-min long surgery without desaturation occurring [73].
HFNO may also be used in children, including in premature 
babies, who are undergoing airway surgeries. For example, a 
report describes the successful use of HFNO (at the flow rate of 
2 L/kg/min) in more than 30 children (aged 6 days to 13 years) 
undergoing airway surgeries (e.g., aryepiglottoplasty, subglot-
tic cyst excisions, tracheal dilatations, and endoscopic cricoid 
splints) [74]. The FiO2 was titrated to maintain the SpO2 at 
95–99%, and spontaneous breathing was successfully preserved 
during surgery. 
A study reported on a premature male baby who had a sub-
glottic web after repeated tracheal intubations. He had severe 
inspiratory stridor that required laser resection and dilatation 
under general anesthesia [68]. Anesthesia was induced with 
sevoflurane and maintained with an infusion of propofol and 
remifentanil. Rocuronium was used to induce a full neuro-
muscular blockade, and an uncuffed tube was inserted. The 
surgeon placed the Parsons laryngoscope using the suspension 
apparatus. For the resection of the subglottic web, the trachea 
was extubated until the SpO2 fell to 80%, following which it was 
re-intubated. The apnea time was 39 and 41 s; however, it could 
be increased to 95 and 160 s when HFNO with a flow rate of 4 
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L/kg/min and an FiO2 of 0.3 was applied. When HFNO with an 
FiO2 of 1.0 was used, the apnea time extended to over 4 min. 
Following 2–4 min of apnea during HFNO, the EtCO2 was mea-
sured as 48–66 mmHg. This case report indicates that HFNO is 
efficient in extending the safe apnea time in an infant undergo-
ing laryngeal repair even with a low FiO2 of 0.3. 
Complications
Several complications associated with the use of HFNO 
during airway surgery have been reported. 
Hypoxemia
One of the major complications associated with the use of 
HFNO during airway surgeries is the failure to maintain oxy-
genation. For example, in a report on the use of HFNO at a flow 
rate of 50 L/min during laryngomicrosurgery [75], the SpO2 
decreased to 72% in 1 of the 23 studied patients, and tracheal 
intubation was temporarily required. In this case, HFNO was 
restarted, and the surgery could be completed without further 
complications.
In 20 infants and children (aged between 5 days to 15 years) 
who were undergoing upper airway surgeries or dynamic air-
way assessments lasting between 3–61 min, oxygenation was 
maintained via HFNO, but 1 of the neonates required rescue 
tracheal intubation at 3 min following apnea due to desaturation 
of 77% [76]. In a 35-year-old man with a parapharyngeal mass 
and a narrowing of the trachea to 4 mm, an emergency surgical 
tracheostomy was performed under sedation while HFNO at a 
flow rate of 30 L/min was applied with the patient in a 40° head-
up position [77]. When the sedation level was deepened, the 
respiratory rate decreased, and complete airway obstruction 
occurred. The SpO2 rapidly decreased to 89%, and an immediate 
tracheostomy was required. This case indicates that if the airway 
is obstructed, HFNO could delay but not prevent the onset of 
hypoxemia. 
Excessive hypercapnea
Hypercapnea is another major complication that occurs 
during airway surgeries because unlike short periods of apneic 
oxygenation before tracheal intubation, apneic oxygenation 
during airway surgery could last for as long as 40–60 min. There 
have been some reports on excessive hypercapnea requiring 
tracheal intubation or jet ventilation [78]. For example, in a 
case series on 30 non-obese patients who underwent elective 
short laryngeal procedures, HFNO at a flow rate of 70 L/min 
was applied while the patients were under apnea during surgery, 
and the surgeon inserted a rigid tubular laryngoscope [79]. In 
1 of the patients, HFNO had to be stopped, and supraglottic jet 
ventilation was required because the PaCO2 exceeded a prede-Ta
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termined threshold of 11 kPa.
Compared with low-flow oxygenation, HFNO enables a 
greater clearance of carbon dioxide [71]. When HFNO (70–80 
L/min) is used in adults for apneic oxygenation, the EtCO2 in-
creases at a rate of 0.12–0.17 kPa/min [59,71,79]. By maintaining 
spontaneous breathing, the increase in EtCO2 can be reduced 
further (e.g., 0.03 kPa/min) [70].
The increase in EtCO2 progresses much faster in children 
than in adults. For example, in children weighing 10–20 kg, the 
mean rate of increase in tcCO2 was 0.55 kPa/min [47]. Younger 
children exhibited a more rapid carbon dioxide increase [47]. 
In a case report on infants weighing 4 kg, the EtCO2 increased 
from 35 mmHg to 51–52 mmHg after 250–251 s of apnea with 
HFNO at a rate of 4 L/kg/min [68].
One feature of the increase in carbon dioxide during apnea 
is that for an initial 1–2 min, the amount of carbon dioxide 
increases rapidly and then slows down [80]. For example, in a 
study [80], apnea increased the PaCO2 at a rate of 12 mmHg/
min in the first minute, followed by a slow rise to 3.4 mmHg/
min.
The exact mechanism of carbon dioxide clearance during 
HFNO is unclear although cardiogenic oscillations, dead space 
gas mixing, and micro-ventilation induced by pharyngeal pres-
sure variations appear to be important factors [81]. 
Airway fire
Airway fire is a well-known complication that can occur 
during head and neck surgeries using lasers. Ignition sources, 
such as diathermy or laser rays, may come into accidental con-
tact with inflammable items, such as tracheal tubes or surgical 
drapes, in an oxygen rich environment, and surgical fire can oc-
cur [82]. If HFNO is used during laser airway surgeries, a high 
concentration of oxygen flows through the surgical field of the 
airway, making it easier to ignite when the electrosurgical devic-
es come into contact with this fuel. A case report on a 65-year-
old female patient has been presented [83]. She was scheduled 
to receive a palatal biopsy. She had titanium dental implants in 
order to attach a palatal obturator following a previous surgery. 
HFNO at a rate of 30 L/min and an FiO2 of 1.0 was used while 
she was spontaneously breathing following the administration of 
propofol and fentanyl. A burn occurred on the diathermy shaft 
when the surgeon used a diathermy device to achieve hemosta-
sis at the biopsy site. Fortunately, the tissue of the patient was not 
harmed. It is recommended that during the use of HFNO, the 
FiO2 should be lowered to the minimum level [71]. One possible 
method is to titrate the FiO2 to 0.3 using a gas blender [70]. It is 
recommended that clinicians be constantly vigilant concerning 
the risk of airway fires during laser or diathermy procedures.
Settings of HFNO during surgery
When it is planned that HFNO is going to be employed for 
oxygenation during airway surgeries, special care needs to be 
taken with regard to the anesthesia method, airway patency, 
breathing mode, oxygen concentration, flow rate, and topicaliza-
tion of the airway in order to maximize the margin of safety. 
Anesthesia needs to be maintained with intravenous anesthe-
sia techniques, such as the TCI of propofol [44,70,72,73,75,79] 
or its continuous infusion [59,68,71,76,78], because inhalational 
anesthetic agents cannot be administered via the HFNO system 
as they would be washed out with the high flow of gases, thereby 
not facilitating the adequate depth of anesthesia [84]. 
The reported flow rates of HFNO vary from 50 L/min [75] 
to 80 L/min [44,59,70–73,78,79] in adults, and a flow rate ≥ 50 
L/min appears to be adequate. In children, the flow rate should 
be adjusted based on the body weight [68,76]. The FiO2 may be 
adjusted, but it would be safer to start with 1.0.
When performing apneic oxygenation, it is necessary to make 
sure that the airway is not obstructed during airway surgeries. 
The jaw thrust method may frequently be required to maintain 
airway patency [59,70,71,78,79]. In the case of microlaryngeal 
surgery, the surgeon usually inserts a suspension laryngoscope 
around the glottis, and this device may help to maintain airway 
patency during surgery [68,70–72]. It may be useful for surgeons 
to insert a tubular laryngoscope to ensure that the dorsal part of 
the laryngeal inlet is open in order to allow oxygen flow [79]. It 
should be kept in mind, however, that suspension laryngoscopy 
is accompanied with an opened mouth, and this may limit the 
ability of HFNO to generate positive airway pressure [71]. 
HFNO may be used both in patients who are apneic 
[59,68,71–73,75,78,79] and in those who are breathing spon-
taneously [44,70,74,76,77]. The preservation of spontaneous 
breathing may permit a better control on the increase in carbon 
dioxide, airway patency, and oxygenation [44]. Additionally, 
spontaneous breathing may aid surgeons in locating the glottis 
by facilitating the confirmation of bubbling or the movement of 
the vocal cords even in the presence of severe laryngeal edema 
obscuring the anatomy. Spontaneous breathing could reduce the 
risk of neuromuscular blockade-induced complete airway ob-
struction. 
To maintain spontaneous breathing, adequate titration of 
the sedative or anesthetic agents to maintain deep sedation and 
adequate topicalization of the upper airway are required; this 
makes sure that the patient can tolerate a surgery in the airway 
[70,74,76]. One method is to perform laryngoscopy and to spray 
a local anesthetic in the airway before performing the airway 
surgery [70]. The risk of airway reactivity increases when the 
neuromuscular blockade is not sufficient, topicalization of the 
airway is not adequate, and repeated attempts at the insertion of 
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surgical instruments are required. In a case report on an infant 
undergoing laryngeal repair, it was outlined that the surgical 
procedure may require multiple attempts at intubation and ex-
tubation alongside a full neuromuscular blockade [68]. In addi-
tion, surgical stimulation varies constantly during a surgery, and 
sedative agents have to be titrated continuously in response to 
patient and surgical conditions; this may result in the sedation 
being too deep, which is associated with accidental and sudden 
apnea [70]. 
Acute respiratory acidosis due to an increase in carbon di-
oxide during apnea does not act as a significant risk [79]. In 
addition, moderate carbon dioxide accumulation of up to 100 
mmHg is not associated with cardiac arrhythmia or sympathetic 
stimulation [59,85] whereas severe carbon dioxide retention of 
more than 100 mmHg is associated with delayed recovery, ICU 
admission, and complications, such as postoperative congestive 
heart failure [85]. Patients who are at a risk of carbon dioxide 
increase, such as those suffering from pulmonary hypertension, 
obstructive airway diseases, raised intracranial pressure, and 
cardiac dysrhythmia, may be excluded from the use of HFNO. 
As there is a strong correlation between the tcCO2 and arterial 
PaCO2, monitoring the tcCO2 should be useful to detect hyper-
capnea [78,79].
Backup plan
Clinicians should be aware of the possibility that desaturation 
could occur during surgery and must have a backup plan to per-
form other oxygenation techniques. One of the plans is the use 
of jet ventilation. In a report on a patient who had tracheobron-
chomalacia with a BMI of 34 kg/m2 and on another patient who 
had spasmodic dysphonia with a BMI of 52 kg/m2, desaturation 
occurred during surgery, but jet ventilation was successfully es-
tablished to increase the saturation [59]. In another report [73], 
infraglottic jet insufflation via cannula cricothyroidotomy was 
considered in order to reverse desaturation as this method does 
not interfere with the ongoing surgery. 
In emergencies such as acute epiglottitis [44] or supraglot-
tic-pharyngeal stenosis [72], clinicians should always keep in 
mind the possibility of a failure of HFNO and a priori prepare 
for emergency tracheostomy. The front of the neck should be 
evaluated thoroughly preoperatively, and the surgeon should be 
immediately available in the event of complete airway obstruc-
tion. In a case series [78], tracheal intubation with a smaller tube 
or supraglottic jet ventilation was planned before apneic oxygen-
ation and was performed when the tcCO2 reached 70 mmHg. 
Summary of the Efficacy of HFNO
HFNO for the induction of anesthesia
It seems reasonable to conclude that HFNO is a superior 
technique to conventional oxygenation techniques in adults and 
children who require tracheal intubation in the operating room 
(Fig. 3). Regarding specific populations, such as those who 
are obese, pregnant, or in need of rapid-sequence induction of 
anesthesia, HFNO may be a feasible technique for delaying the 
onset of hypoxemia. In contrast, the efficacy of the use of HFNO 
in the case of critically ill patients remains unclear. Because the 
number of reported clinical trials is still insufficient and because 
of conflicting results, the most adequate protocol and indica-
tions for the use of HFNO should be explored and standardized 
via larger clinical trials.
When the first attempt at tracheal intubation fails, an im-
mediate decision should be made as to whether and when bag-
mask ventilation should be commenced. If a facemask is used 
during preoxygenation and if a nasal cannula is used only 
during the apneic periods in the case of a laryngoscopy until 
the tracheal tube insertion is completed, the nasal cannula may 
impair efficient preoxygenation via the facemask by introducing 
A B
Fig. 3. High-flow nasal oxygenation 
for tracheal intubation in the operating 
room. (A) Preoxygenation. (B) Apneic 
oxygenation (© Fisher & Paykel Health-
care 2018. Used with permission).
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oxygen leaks and the entrainment of room air [86]. When a na-
sal cannula is used together with a facemask, oxygen insufflation 
at a flow rate of 10 L/min or greater is recommended [86].
HFNO may be the most relevant in patients who are going to 
undergo rapid-sequence induction of anesthesia, which involves 
a relatively short apneic period (i.e., 1 min), compared to in 
those who are scheduled to undergo a conventional technique 
for the induction of anesthesia in which bag-mask ventilation 
can be avoided [36,39]. If it takes more than 3–4 min to secure 
the airway and if bag-mask ventilation is appropriate, then it 
may be less useful to employ HFNO because the oxygen satu-
ration may decrease further in response to passive apneic ox-
ygenation compared to with active bag-mask ventilation [10]. 
Nevertheless, the majority of cases involving difficult oxygen-
ation after the induction of anesthesia cannot be predicted pre-
operatively [87], and thus, some researchers suggest that HFNO 
should be carried out in all the patients who receive anesthesia 
[22]. At the same time, clinicians should be aware that HFNO is 
not an adequate approach for recovering the SpO2 when signifi-
cant desaturation occurs. Therefore, before the induction of an-
esthesia, preoperative airway assessments should be performed 
meticulously, and an airway strategy should be developed with a 
backup plan. 
It should be considered that the use of HFNO should be 
added to the difficult airway guidelines and that its areas of ap-
plication should be expanded to special populations such as to 
those with reduced cardiopulmonary reserve, to children, and to 
obese and pregnant patients [88]. 
HFNO for airway surgery
Adequate communication, understanding, and teamwork are 
essential in order to establish intraoperative oxygenation using 
HFNO during airway surgeries. HFNO should not preclude the 
use of an alternate oxygenation plan, which should be made pre-
operatively, to resolve significant desaturation, hypercarbia, and 
acidosis. Therefore, sufficient planning and preparation should 
be carried out prior to preoxygenation. For short-duration sur-
geries, an increase in carbon dioxide and not the oxygenation 
technique may be the factor that determines the duration of 
apnea. TcCO2 monitoring is recommended for long procedures 
that last for more than 30 min [89]. 
Conclusions
HFNO is a promising new technique that keeps patients safer 
during anesthesia. Despite the mounting evidence supporting 
its use, more research and clinical trials are needed in order to 
establish the ideal use of this technique in various populations. 
We hope that this review will help readers to understand the rel-
evant techniques involved in the use of HFNO and to facilitate 
the introduction of its use into the Airway Management Guide-
lines in the future.
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